Eli Lilly beats Novo to oral China GLP-1RA market on NMPA approval
Eli Lilly has beaten its staunch obesity rival Novo Nordisk to market in China by securing an approval for its…
12 Nov 2026
Blackstone backs Pfizer’s obesity ambitions with $1.5bn fund
With an eye on entering the obesity market dominated by Eli Lilly, Pfizer has secured $1.5bn from Blackstone Life Sciences to spur clinical development of its monthly glucagon-like peptide-1 receptor…
12 Nov 2026
Beyond GLP-1RA’s: Novel mechanisms and combos to shape future of obesity market
In recent years, the emergence of the incretin drug class has revolutionised the cardiometabolic treatment space, as doctors increasingly prescribe weight loss medications for the long-term management of obesity and…
12 Nov 2026
FDA and EMA waive paediatric studies for Shanton’s gout candidate
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have granted paediatric clinical trial waivers to Shanton Pharma for its lead candidate SAP-001, easing the drug's…
12 Nov 2026
Life-extending peptides are likely not around the corner
Excitement in the longevity space over peptides comes with the caveat that many claims about their life-extending potential are incomplete at best and unfounded at worst. Interest around longevity research…
12 Nov 2026
Litmys and PharmaACE partner on pharma commercial forecasting
Life sciences consulting firms Litmys and PharmaACE have formed a strategic collaboration to provide commercial forecasting and decision-making services to the pharmaceutical and biotechnology sectors. The partnership links real-world product…
11 Nov 2026
AstraZeneca acquires bacterial vaccine biotech, Omniose
After two years of fruitful collaboration, AstraZeneca is opting to acquire its partner and bacterial vaccine technology startup, Omniose. For an undisclosed sum, AstraZeneca will incorporate the preclinical biotech into…